FEIBA: A prohemostatic agent

Caroline Cromwell, Louis M. Aledort

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Factor eight inhibitor bypassing activity (FEIBA), Anti-Inhibitor Coagulation Complex has been used for over 30 years in hemophiliac patients with inhibitors. The history of its use is reviewed here, including issues related to thrombosis, efficacy, and comparison to alternative bypassing agents. The need for surrogate assays to monitor effective hemostasis with the use of FEIBA remains.

Original languageEnglish
Pages (from-to)265-267
Number of pages3
JournalSeminars in Thrombosis and Hemostasis
Issue number3
StatePublished - 2012


  • factor eight inhibitor bypassing activity
  • hemophilia
  • inhibitors
  • thrombosis


Dive into the research topics of 'FEIBA: A prohemostatic agent'. Together they form a unique fingerprint.

Cite this